A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

The efficacy and safety of clobetasol propionate 0.05% scalp application was evaluated in 378 patients with moderate to severe scalp psoriasis in a double-blind vehicle-controlled parallel group study. After 2 weeks of twice-daily applications, 81% receiving active drug versus 22% receiving vehicle had clearing of 50% or greater. Complete clearing was seen in 26% with active drug and 1% with vehicle. Local side effects were primarily burning or stinging in 11% and 10% of patients treated on an active or a vehicle regimen, respectively. The morning cortisol levels of 168 patients were checked at baseline and again after 2 weeks of drug therapy. Subnormal morning plasma cortisol values were seen in 5% of the patients receiving active drug and in 5% receiving vehicle; 13% of those taking active drug versus 5% taking vehicle had a 50% or greater decrease in morning cortisol at the 2-week visit compared with baseline values. Clobetasol propionate 0.05% scalp application appears to be a safe and an effective treatment for scalp psoriasis.

Full Text

Duke Authors

Cited Authors

  • Olsen, EA; Cram, DL; Ellis, CN; Hickman, JG; Jacobson, C; Jenkins, EE; Lasser, AE; Lebwohl, M; Leibsohn, E; Medansky, RS

Published Date

  • March 1, 1991

Published In

Volume / Issue

  • 24 / 3

Start / End Page

  • 443 - 447

PubMed ID

  • 2061442

International Standard Serial Number (ISSN)

  • 0190-9622

Digital Object Identifier (DOI)

  • 10.1016/0190-9622(91)70069-e


  • eng

Conference Location

  • United States